EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation

Aina Xiao, Yu'E Liu iD, Wenjia Guo iD

Cancers · 09.05.2026 · 18 (10) · 1530

DOI: 10.3390/cancers18101530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 09.05.2026. Verfasst von Aina Xiao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan 750002, China. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with limited effective therapies. Dihydroartemisinin (DHA), a derivative of artemisinin, exhibits potent antitumor activity, but its molecular mechanisms in HCC are unclear. Here, we identified kinesin family member 11 (KIF11) as a critical effector of DHA.

Methods

Bioinformatic analyses revealed that KIF11 is significantly upregulated in HCC and associated with poor prognosis, and gene expression profiling suggested its oncogenic role via the PI3K/Akt pathway. Functional studies demonstrated that DHA inhibits HCC cell proliferation, migration, invasion, and colony formation, while inducing apoptosis. Xenograft models of nude mice were established for validation.

Results

DHA downregulated KIF11 and epithelial–mesenchymal transition markers, whereas KIF11 overexpression attenuated DHA’s inhibitory effects; the inhibition of PI3K restored DHA sensitivity in KIF11-overexpressing cells. In vivo, DHA markedly suppressed tumor growth and malignancy in xenograft models, consistent with modulation of KIF11 and EMT-related proteins.

Conclusions

DHA exerts antitumor effects in HCC by acting via KIF11 and PI3K/Akt modulation, providing a potential therapeutic strategy.

Schlagwörter

Stichwörter der Autor:innen

KIF11PI3K/Akt signalingapoptosisdihydroartemisininhepatocellular carcinoma

Autor:innen und Institutionen

  • Department of Blood Transfusion, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan 750002, China.
  • Department of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

ORCID-Profile: Yu'E Liu, Wenjia Guo

Zitieren

APA

Xiao, A., Liu, Y., & Guo, W. (2026). Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation. Cancers, 18(10), 1530. https://doi.org/10.3390/cancers18101530

Vancouver

Xiao A, Liu Y, Guo W. Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation. Cancers. 2026;18(10):1530. doi:10.3390/cancers18101530

BibTeX
@article{Xiao2026,
  author = {Xiao, Aina and Liu, Yu'E and Guo, Wenjia},
  title = {Dihydroartemisinin Suppresses Hepatocellular Carcinoma Progression by Acting on KIF11 with PI3K/Akt Modulation},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1530},
  doi = {10.3390/cancers18101530}
}
Kostenlos starten →